keyword
MENU ▼
Read by QxMD icon Read
search

overall survival breast cancer

keyword
https://www.readbyqxmd.com/read/28445946/dose-invasive-apocrine-adenocarcinoma-has-worse-prognosis-than-invasive-ductal-carcinoma-of-breast-evidence-from-seer-database
#1
Ning Zhang, Hanwen Zhang, Tong Chen, Qifeng Yang
BACKGROUND: Invasive apocrine adenocarcinoma (AAC) of breast is a rare histopathological subtype of breast carcinomas. We aim to investigate the different characteristics and prognostic outcomes between AAC and invasive ductal carcinoma (IDC) of breast cancer. RESULTS: AAC patients presented with older ages, more aggressive behaviors, lower ER and PR proportions, higher HER2 amplification rates and less application of breast-conserving therapy and adjuvant chemotherapy compared to IDC patients...
April 11, 2017: Oncotarget
https://www.readbyqxmd.com/read/28445153/increased-risk-of-brain-metastases-in-women-with-breast-cancer-and-p16-expression-in-metastatic-lymph-nodes
#2
Elise Furet, Morad El Bouchtaoui, Jean-Paul Feugeas, Catherine Miquel, Christophe Leboeuf, Clémentine Beytout, Philippe Bertheau, Emilie Le Rhun, Jacques Bonneterre, Anne Janin, Guilhem Bousquet
PURPOSE: Metastatic breast cancer is a leading cause of mortality in women, partly on account of brain metastases. However, the mechanisms by which cancer cells cross the blood-brain barrier remain undeciphered. Most molecular studies predicting metastatic risk have been performed on primary breast cancer samples. Here we studied metastatic lymph-nodes from patients with breast cancers to identify markers associated with the occurrence of brain metastases. RESULTS: Transcriptomic analyses identified CDKN2A/p16 as a gene potentially associated with brain metastases...
April 8, 2017: Oncotarget
https://www.readbyqxmd.com/read/28442763/impact-of-hormone-receptor-status-and-distant-recurrence-free-interval-on-survival-benefits-from-trastuzumab-in-her2-positive-metastatic-breast-cancer
#3
Hai-Yuan Yang, Ding Ma, Yi-Rong Liu, Xin Hu, Jian Zhang, Zhong-Hua Wang, Gen-Hong Di, Xi-Chun Hu, Zhi-Ming Shao
We sought to investigate the impact of hormone receptor (HR) status and distant recurrence-free interval (DRFI) on the degree of overall survival (OS) benefit from palliative trastuzumab-containing treatment in HER2-positive metastatic breast cancer (MBC). Here, we retrospectively identified 588 eligible HER2-positive patients with postoperative distant recurrence. DRFI of HR+HER2+ MBC patients (median: 30.7 months, IQR: 18.5-45.9, P < 0.001) was significant longer compared with HR-HER2+ patients. Patients were categorized into four subgroups based on HR status and palliative trastuzumab (trast+) received...
April 25, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28442559/impact-of-27-hydroxylase-cyp27a1-and-27-hydroxycholesterol-in-breast-cancer
#4
Siker Kimbung, Chingyi Chang, Pär-Ola Bendahl, Laura Dubois, Will J Thompson, Donald P McDonnell, Signe Borgquist
The impact of systemic 27-hydroxycholesterol (27HC) and intra-tumoral CYP27A1 expression on pathobiology and clinical response to statins in breast cancer needs clarification. 27HC is an oxysterol produced from cholesterol by the monooxygenase CYP27A1, which regulates intracellular cholesterol homeostasis. 27HC also acts as an endogenous selective estrogen receptor (ER) modulator capable of increasing breast cancer growth and metastasis. 27HC levels can be modulated by statins or direct inhibition of CYP27A1, thereby attenuating its pro-tumorigenic activities...
April 25, 2017: Endocrine-related Cancer
https://www.readbyqxmd.com/read/28440460/triple-negative-breast-cancer-new-therapeutic-options-via-signalling-transduction-cascades
#5
Ulrich Andergassen, Alexandra C Kölbl, Jan-Niclas Mumm, Sven Mahner, Udo Jeschke
Triple-negative breast cancer is a highly aggressive type of mammalian carcinoma. It is defined by a rather weak expression of estrogen-, progesterone- and Her2-receptor, and is thus difficult to treat, resulting in low disease-free and overall survival rates of the affected patients. Hence it is important to find new therapeutic options. To this aim we analysed the incidence of some molecules from different signal transduction cascades by immunohistochemistry, which are known to correlate with triple-negative breast cancer, and correlated the expression of these molecules to different tumour traits, such as size, grading, menopausal stage, histology, lymph node affection, remote metastasis formation, and to the incidence of local and lymph node recurrence and metastasis by statistical analysis...
May 2017: Oncology Reports
https://www.readbyqxmd.com/read/28439713/personalized-axillary-dissection-the-number-of-excised-lymph-nodes-of-nodal-positive-breast-cancer-patients-has-no-significant-impact-on-relapse-free-and-overall-survival
#6
Florian Ebner, Achim Wöckel, Wolfgang Janni, Rolf Kreienberg, Lukas Schwentner, Manfred Wischnewsky
PURPOSE: Sentinel lymph node (SLN) biopsy has replaced axillary lymph node dissection (ALND) for the staging of clinically node-negative breast cancer patients (BCP), demonstrating equivalent survival to ALND while resulting in reduced morbidity. ALND has remained the standard of care for the majority of BCP with clinical axillary metastases or metastases found on SLN biopsy. More recently, it is debated whether ALND could be avoided not only in SLN-negative BCP but also in selected SLN-positive disease or even in all patients...
April 24, 2017: Journal of Cancer Research and Clinical Oncology
https://www.readbyqxmd.com/read/28439493/targeted-therapies-in-breast-cancer-new-challenges-to-fight-against-resistance
#7
REVIEW
Viviana Masoud, Gilles Pagès
Breast cancer is the most common type of cancer found in women and today represents a significant challenge to public health. With the latest breakthroughs in molecular biology and immunotherapy, very specific targeted therapies have been tailored to the specific pathophysiology of different types of breast cancers. These recent developments have contributed to a more efficient and specific treatment protocol in breast cancer patients. However, the main challenge to be further investigated still remains the emergence of therapeutic resistance mechanisms, which develop soon after the onset of therapy and need urgent attention and further elucidation...
April 10, 2017: World Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28437161/randomized-phase-iii-trial-of-trastuzumab-plus-capecitabine-with-or-without-pertuzumab-in-patients-with-human-epidermal-growth-factor-receptor-2-positive-metastatic-breast-cancer-who-experienced-disease-progression-during-or-after-trastuzumab-based-therapy
#8
Ander Urruticoechea, Mohammed Rizwanullah, Seock-Ah Im, Antonio Carlos Sánchez Ruiz, István Láng, Gianluca Tomasello, Hannah Douthwaite, Tanja Badovinac Crnjevic, Sarah Heeson, Jennifer Eng-Wong, Montserrat Muñoz
Purpose To assess the efficacy and safety of trastuzumab plus capecitabine with or without pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who experienced disease progression during or after trastuzumab-based therapy and received a prior taxane. Patients and Methods Patients were randomly assigned to arm A: trastuzumab 8 mg/kg → 6 mg/kg once every 3 weeks plus capecitabine 1,250 mg/m(2) twice a day (2 weeks on, 1 week off, every 3 weeks); or arm B: pertuzumab 840 mg → 420 mg once every 3 weeks plus trastuzumab at the same dose and schedule as arm A plus capecitabine 1,000 mg/m(2) on the same schedule as arm A...
April 24, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28436378/outcomes-of-corpectomy-in-patients-with-metastatic-cancer
#9
Grzegorz Guzik
BACKGROUND: The objective of surgical management of spinal metastases is to reduce pain and improve the patient's quality of life. The operation should restore spinal stability and decompress neural structures. One surgical technique is corpectomy followed by vertebral body reconstruction and stabilisation of the spine. The procedure may be performed in patients in overall good health and a good survival prognosis. The aim of this paper is to present the outcomes of surgical management of spinal metastases in patients who underwent corpectomy followed by vertebral body reconstruction and stabilisation of the spine...
January 26, 2017: Ortopedia, Traumatologia, Rehabilitacja
https://www.readbyqxmd.com/read/28435404/phase-ii-study-of-adjuvant-docetaxel-and-carboplatin-with-without-doxorubicin-and-cyclophosphamide-in-triple-negative-breast-cancer-a-randomised-controlled-clinical-trial
#10
Safa Najafi, Mehrdad Payandeh, Masoud Sadeghi, Vahideh Shafaei, Fateme Shojaiyan, Fereshte Abbasvandi
AIM OF THE STUDY: The aim of this trial was to compare overall survival (OS), disease-free survival (DFS), and toxicity of two adjuvant regimens in triple negative patients with Iranian ethnicity. MATERIAL AND METHODS: In a phase II trial, patients with previously untreated triple negative breaststroke cancer were randomly assigned by using docetaxel 70 mg/m(2) and carboplatin AUC = 7 every three weeks with granulocyte colony-stimulating factor for sin courses (arm A) or doxorubicin hydrochloride 60 mg/m(2) and cyclophosphamide 600 mg/m(2) every three weeks with G-CSF for four courses followed by docetaxel 70 mg/m(2) and carboplatin AUC = 7 every three weeks with G-CSF for four courses (arm B)...
2017: Contemporary Oncology Współczesna Onkologia
https://www.readbyqxmd.com/read/28435291/role-of-postmastectomy-radiotherapy-in-early-stage-t1-2n0-1m0-triple-negative-breast-cancer-a-systematic-review
#11
REVIEW
Fengxia Chen, Feifei Pu
Triple-negative breast cancer (TNBC), which represents 15%-20% of all breast cancers, is defined by the absence of estrogen receptor (ER) and progesterone receptor (PR) and overexpression of human epidermal growth factor receptor 2 (HER2). Owing to the absence of specific therapeutic targets and its aggressive biologic characteristics, TNBC patients often experience a high risk of disease progression and poor overall survival. Furthermore, TNBC exhibits an early pattern of recurrence with a peak recurrence risk at 2-3 years after surgery...
2017: OncoTargets and Therapy
https://www.readbyqxmd.com/read/28432855/a-systematic-review-of-psychotherapeutic-interventions-for-women-with-metastatic-breast-cancer-context-matters
#12
REVIEW
Lisa Beatty, Emma Kemp, Phyllis Butow, Afaf Girgis, Penelope Schofield, Jane Turner, Nicholas J Hulbert-Williams, Janelle V Levesque, Bogda Koczwara
OBJECTIVES: To summarise the evidence-base of psychological interventions for women with metastatic breast cancer (MBC), by mode of delivery (group, individual, or low-intensity interventions). To synthesise data regarding core intervention-elements (e.g., intervention duration) and context factors (trial setting, uptake and adherence, demographic characteristics). METHODS: Four databases were searched (inception - May 2016): MEDLINE (OvidSP), PsycINFO (OvidSP), CINAHL (EBSCO), and SCOPUS; reference lists were examined for additional publications...
April 22, 2017: Psycho-oncology
https://www.readbyqxmd.com/read/28432513/the-relationship-between-statins-and-breast-cancer-prognosis-varies-by-statin-type-and-exposure-time-a-meta-analysis
#13
EDITORIAL
Binliang Liu, Zongbi Yi, Xiuwen Guan, Yi-Xin Zeng, Fei Ma
PURPOSE: Breast cancer is the most common cancer in females and the leading cause of death worldwide. The effects of statins on breast cancer prognosis have long been controversial; thus, it is important to investigate the relationship between statin type, exposure time, and breast cancer prognosis. This study sought to explore the effect of statins, as well as the different effects of statin solubility and variable follow-up times, on breast cancer prognosis. METHODS: We searched the MEDLINE (via PubMed), EMBASE (via OvidSP), Cochrane Library, and ISI Web of Knowledge databases using combinations of the terms "breast neoplasms[MeSH]," "statins" or "lipid-lowering drug," "prognosis" or "survival," or "mortality" or "outcome" with no limit on the publication date...
April 21, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28432512/squamous-cell-carcinoma-of-the-breast-in-the-united-states-incidence-demographics-tumor-characteristics-and-survival
#14
Siddhartha Yadav, Dhiraj Yadav, Dana Zakalik
PURPOSE: Squamous cell carcinoma of breast accounts for less than 0.1% of all breast cancers. The purpose of this study is to describe the epidemiology and survival of this rare malignancy. METHODS: Data were extracted from the National Cancer Institute's Surveillance, Epidemiology and End Results Registry to identify women diagnosed with squamous cell carcinoma of breast between 1998 and 2013. SEER*Stat 8.3.1 was used to calculate age-adjusted incidence, age-wise distribution, and annual percentage change in incidence...
April 21, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28430626/expression-of-pd-l1-and-prognosis-in-breast-cancer-a-meta-analysis
#15
Minghui Zhang, Houbin Sun, Shu Zhao, Yan Wang, Haihong Pu, Yan Wang, Qingyuan Zhang
The associations between programmed cell death ligand 1 (PD-L1) and the prognosis of various cancers have always been a research topic of considerable interest. However, the prognostic value of PD-L1 in breast cancer patients remains a controversial subject. We aimed to assess the association between PD-L1 protein expression and clinicopathological features and the impact of this relationship on breast cancer survival. We performed a systematic search of the PubMed, EMBASE, and Cochrane Library databases to determine the correlations among PD-L1 expression, clinicopathological features and overall survival (OS)...
February 20, 2017: Oncotarget
https://www.readbyqxmd.com/read/28429898/subclassification-of-the-molecular-types-of-breast-cancer-based-on-the-expression-of-immunohistochemical-markers-and-evolution
#16
Aldo Reigosa, David Hardisson, Francisco Sanzi, Eduardo Caleiras, Felipe Saldivia, Angel Fernández
Breast carcinomas have been classified from the molecular point of view into four major groups (Luminal A, Luminal B, HER2 and triple negative). However, these groups are not homogeneous and there is a need to establish subcategories that can be identified by immunohistochemistry (IHC), to better predict prognosis and carry out treatments that are more effective. This study was conducted in 354 patients diagnosed with invasive ductal breast carci- noma. The expression of 22 molecules was analyzed by tissue matrices and the results obtained were compared with molecular classes defined by IHC, according to the expression of estrogen receptor (ER), progesterone receptor (PR) and HER2, and the overall survival...
June 2016: Investigación Clínica
https://www.readbyqxmd.com/read/28429422/retrospective-evaluation-of-premenopausal-hormone-sensitive-breast-cancer-patients-treated-with-adjuvant-gonadotropin-releasing-hormone-analogue-anatolian-society-of-medical-oncology-asmo-study
#17
Ayşe Demirci, Necati Alkış, Faysal Dane, Ayşe Durnalı, Ömer Kamil Yazıcı, Rashad Rzayev, Serap Kaya, Doğan Yazılıtaş, Mevlüde İnanç, Melike Özçelik, Tülay Akman, Mehmet Ali Kaplan, Yusuf Günaydın, Arife Ulaş, Özlem Sönmez, Saadet Tokluoğlu, Gamze Gököz Doğu, Öznur Bal, Mahmut Gümüş
AIM: The goal of this study is to evaluate possible factors affecting the survival of patients treated with gonadotropin-releasing hormone (GnRH) analogues. METHODS: Demographic characteristics, treatment modalities, overall survival (OS) and the possible factors affecting the survival a total of 554 premenopausal breast cancer patients in Turkey evaluated retrospectively. RESULTS: The median duration of GnRH analogues use was 22 ± 13.6 (range, 1-87) months...
April 21, 2017: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28429102/improved-systemic-treatment-for-early-breast-cancer-improves-cure-rates-modifies-metastatic-pattern-and-shortens-post-metastatic-survival-35-year-results-from-the-munich-cancer-registry
#18
Dieter Hölzel, Renate Eckel, Ingo Bauerfeind, Bernd Baier, Thomas Beck, Michael Braun, Johannes Ettl, Ulrich Hamann, Marion Kiechle, Sven Mahner, Christian Schindlbeck, Johann de Waal, Nadia Harbeck, Jutta Engel
PURPOSE: Systemic therapies (ATHs) in early breast cancer have improved the survival of breast cancer (BC) patients in recent decades. The magnitude of the changes in overall, metastasis-free (MFS) and post-metastatic (PMS) survival and in the metastasis (MET) pattern will be described. PATIENT AND METHODS: We analysed 60,227 patients with a diagnosis of T-N-M0 BC between 1978 and 2013 and 11,983 patients with metastases (MET) in the Munich Cancer Registry. Patients will be divided into four time periods to identify relationships between BC and METs...
April 20, 2017: Journal of Cancer Research and Clinical Oncology
https://www.readbyqxmd.com/read/28428887/differential-intratumoral-distributions-of-cd8-and-cd163-immune-cells-as-prognostic-biomarkers-in-breast-cancer
#19
Sotirios P Fortis, Michael Sofopoulos, Nectaria N Sotiriadou, Christoforos Haritos, Christoforos K Vaxevanis, Eleftheria A Anastasopoulou, Nicole Janssen, Niki Arnogiannaki, Alexandros Ardavanis, Graham Pawelec, Sonia A Perez, Constantin N Baxevanis
BACKGROUND: Tumor immune cell infiltrates are essential in hindering cancer progression and may complement the TNM classification. CD8+ and CD163+ cells have prognostic impact in breast cancer but their spatial heterogeneity has not been extensively explored in this type of cancer. Here, their potential as prognostic biomarkers was evaluated, depending on their combined densities in the tumor center (TC) and the tumor invasive margin (IM). METHODS: CD8+ and CD163+ cells were quantified by immunohistochemistry of formalin-fixed, paraffin-embedded (FFPE) tumor tissue samples from a cohort totaling 162 patients with histologically-confirmed primary invasive non-metastatic ductal breast cancer diagnosed between 2000 and 2015...
2017: Journal for Immunotherapy of Cancer
https://www.readbyqxmd.com/read/28428107/clinicopathologic-factors-associated-with-survival-in-patients-with-breast-cancer-brain-metastasis
#20
Rong Li, Kui Zhang, Gene P Siegal, Shi Wei
Brain metastasis from breast cancer generally represents a catastrophic event yet demonstrates substantial biological heterogeneity. There have been limited studies solely focusing on the prognosis of patients with such metastasis. In this study, we carried out a comprehensive analysis in 108 consecutive patients with breast cancer brain metastases between 1997 and 2012 to further define clinicopathologic factors associated with early onset of brain metastasis and survival outcomes after development of them...
April 17, 2017: Human Pathology
keyword
keyword
107111
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"